These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33074364)

  • 1. Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report.
    Arigami T; Matsushita D; Okubo K; Tanaka T; Sasaki K; Noda M; Kita Y; Mori S; Tsuruda Y; Kurahara H; Ohtsuka T
    Surg Case Rep; 2020 Oct; 6(1):271. PubMed ID: 33074364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report.
    Matsumoto R; Arigami T; Matsushita D; Okubo K; Tanaka T; Yanagita S; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Ohtsuka T
    World J Surg Oncol; 2020 Jul; 18(1):179. PubMed ID: 32693806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer.
    Jun C; Yamauchi S; Yube Y; Egawa H; Yoshimoto Y; Kubota A; Tsuda K; Kaji S; Orita H; Oka S; Mine S; Fukunaga T
    Surg Case Rep; 2023 May; 9(1):86. PubMed ID: 37204618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Case of Long Survival with Hilar Lymph Node Metastasis from Gastric Cancer Successfully Treated with Nivolumab Immunotherapy].
    Okada K; Takeoka T; Kobayashi K; Fukunaga M
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2315-2317. PubMed ID: 32156916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy.
    Hayashi M; Fujita T; Matsushita H
    Keio J Med; 2023 Jun; 72(2):60-64. PubMed ID: 36740273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage IV gastric cancer with microsatellite instability-high achieving long-term survival by gastrectomy after nivolumab as third-line therapy: a case report and literature review.
    Kumagai H; Baba S; Nikai H; Fujisawa R; Shimooki M; Sasaki A
    Surg Case Rep; 2024 Sep; 10(1):221. PubMed ID: 39294523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy.
    Doi H; Ninomiya M; Toyota K; Hirahara S; Kuhara Y; Shirakawa K; Yano R; Kobayashi H; Hashimoto Y; Yokoyama Y; Sakashita Y; Miyamoto K
    Int Cancer Conf J; 2020 Oct; 9(4):187-192. PubMed ID: 32904060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report.
    Komo T; Suzuki T; Tazawa H; Sada H; Morimoto H; Shimada N; Hadano N; Onoe T; Sudo T; Shimizu Y; Tashiro H
    Int J Surg Case Rep; 2021 Jul; 84():106161. PubMed ID: 34237686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of gastric cancer showing a durable response after the discontinuation of nivolumab due to the early onset of immune-related adverse events].
    Tomita Y; Mori Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Nomura S; Hirano A; Kimura Y; Tsuchida K; Seno K
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(6):551-557. PubMed ID: 35691925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy.
    Watanabe H; Fujikawa H; Komori K; Kano K; Takahashi K; Yamada T; Inokuchi Y; Machida N; Yokose T; Rino Y; Masuda M; Ogata T; Oshima T
    Case Rep Gastroenterol; 2021; 15(2):562-567. PubMed ID: 34616257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Recurrent Gastric Cancer with Long-Term Control via Two Resections and Multidisciplinary Treatment Including Nivolumab].
    Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab.
    Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Surg Case Rep; 2018 Jul; 4(1):71. PubMed ID: 29978335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion surgery for gastric remnant cancer with liver metastasis after nivolumab combination chemotherapy achieving pathological complete response: a case report and literature review.
    Katsumata K; Morimoto Y; Aoyama J; Yamada T; Katsuki Y; Nishiyama R; Egawa T
    Surg Case Rep; 2024 May; 10(1):107. PubMed ID: 38691201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of Peritoneal Metastasis from an Unresectable Advanced Gastric Cancer with a Good Response to Nivolumab].
    Kumano T; Shibata R; Ota A; Tanaka S; Komatsu S; Imura K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2424-2426. PubMed ID: 33468982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer.
    Uehata N; Kouzu K; Tsujimoto H; Sugasawa H; Wakamatsu K; Kishi Y; Ueno H
    Surg Case Rep; 2021 Apr; 7(1):97. PubMed ID: 33876326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case of Advanced Gastric Cancer in Which Tumor Relapse Was Observed after Discontinuation of Nivolumab Due to Complete Response, and for Which Re-Administration Was Initiated].
    Nishida K; Yagi H; Mizumoto R; Haeno M; Mori S; Nomura M; Yasuyama A; Yoshikawa Y; Sueda T; Matsumura T; Koga C; Miyagaki H; Tei M; Tsujie M; Akamaru Y
    Gan To Kagaku Ryoho; 2023 Mar; 50(3):343-345. PubMed ID: 36927904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of Effective Disease Control of Advanced Gastric Cancer with Distant Lymph Node Metastases Following Nivolumab Treatment].
    Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
    Gan To Kagaku Ryoho; 2020 Aug; 47(8):1258-1260. PubMed ID: 32829368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful R0 resection after chemotherapy, including nivolumab, for gastric cancer with liver metastases: three case reports.
    Kawai J; Yasufuku I; Fukada M; Asai R; Sato Y; Tajima YJ; Saigo C; Kiyama S; Makiyama A; Tanaka Y; Okumura N; Murase K; Miyazaki T; Matsuhashi N
    Surg Case Rep; 2024 Jun; 10(1):138. PubMed ID: 38837046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report.
    Takami T; Yasuda K; Uozumi N; Musiake Y; Shintani H; Kataoka N; Yamaguchi T; Makimoto S
    J Med Case Rep; 2021 Dec; 15(1):604. PubMed ID: 34930435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.